DRCR shapes diabetic retina care

Diabetic retina care now runs on trial protocols, and many of the most influential ones come from the DRCR Retina Network. (retinalphysician.com) The network was founded in 2002 with support from the National Eye Institute, and by 2025 it had grown to more than 1,500 members across North America. Its studies are multicenter trials built to answer practical clinic questions, not just lab questions. (public.jaeb.org) (retinalphysician.com) Start with the disease itself. Diabetic retinopathy damages tiny retinal blood vessels, and diabetic macular edema is swelling in the macula, the part of the retina used for sharp central vision. (nature.com) For years, laser was the standard treatment for diabetic macular edema. DRCR’s Protocol I helped move the field toward anti-vascular endothelial growth factor drugs, showing ranibizumab beat laser for vision outcomes over 5 years. (modernretina.com) (retinalphysician.com) Protocol T then tackled the next clinic question: which anti-VEGF drug to use. In 660 study eyes, aflibercept, bevacizumab, and ranibizumab performed similarly for milder vision loss, but aflibercept did better when baseline vision was 20/50 or worse. (public.jaeb.org) (retinalphysician.com) Protocol V changed care again by asking whether every eye with center-involved edema needs immediate treatment. In eyes with visual acuity of 20/25 or better, initial observation with aflibercept only if vision worsened performed similarly at 2 years to prompt aflibercept or laser. (vitbucklesociety.org) (eye.hms.harvard.edu) That result gave retina clinics permission to watch some patients closely instead of starting injections on day one. It also turned optical coherence tomography and repeat vision checks into a triage tool for deciding who can safely wait. (retinalphysician.com) (public.jaeb.org) Protocol W tested a different idea: treat severe nonproliferative diabetic retinopathy before vision-threatening complications appear. Over 4 years, aflibercept lowered the cumulative probability of proliferative diabetic retinopathy or center-involved edema with vision loss to 33.9% versus 56.9% with sham, but visual acuity change was nearly identical. (eye.hms.harvard.edu) That finding narrowed the case for preventive injections. Doctors can reduce anatomic progression, but the 4-year data did not show better vision, which matters when patients are weighing repeated shots, visit burden, and cost. (eye.hms.harvard.edu) (ophthalmologyadvisor.com) For proliferative diabetic retinopathy, Protocol S established that injections could stand alongside panretinal photocoagulation, the scatter laser used to shrink abnormal new vessels. At 5 years, both approaches preserved vision, while ranibizumab produced less vision-impairing macular edema and less visual-field loss. (vitbucklesociety.org) (eye.hms.harvard.edu) The network also keeps pushing on imaging and sequencing. Protocol AA examined whether ultrawide-field photos and angiography, which capture the retinal far periphery beyond the classic seven-field view, can better predict worsening over time. (public.jaeb.org) (ophthalmologytimes.com) And newer studies show the same pattern: practical questions, protocol answers. Protocol AC compared aflibercept against a bevacizumab-first strategy with a switch at 12 to 20 weeks if eyes met prespecified criteria, directly testing a step-therapy approach many payers and clinics already face. (public.jaeb.org) ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03321513